<DOC>
	<DOCNO>NCT00508469</DOCNO>
	<brief_summary>The purpose study compare adherence patient fix combination travoprost 0.004 % /timolol 0.5 % patient concomitant combination travoprost 0.004 % timolol 0.5 % use Travalert® device .</brief_summary>
	<brief_title>Adherence Assessment With Travalert Dosing Aid</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Diagnosis openangle glaucoma ocular hypertension ; Inadequate control betablocker prostaglandin monotherapy start therapy travoprost 0.004 % timolol 0.05 % ; Intraocular pressure ( IOP ) screen visit least one eye ≥ 19 mmHg exceed 36 mmHg either eye ; Other protocoldefined inclusion criterion may apply . Females childbearing potential currently pregnant , breastfeeding , take control measure prevent pregnancy ; Not currently receive treatment lower IOP betablockers prostaglandin analog ; Currently therapy therapy another investigational agent within 30 day prior baseline visit ; History chronic recurrent severe inflammatory eye disease , history ocular trauma within past six ( 6 ) month , history ocular infection ocular inflammation within past three ( 3 ) month either eye ; History clinically significant progressive retinal disease history severe ocular pathology either eye would preclude administration topical prostaglandin analogue ; History severe serious hypersensitivity prostaglandin drug analogue , topical systemic betablockers , component study medication ; Intraocular surgery within past six ( 6 ) month ocular laser surgery within past three ( 3 ) month determine patient history and/or examination either eye ; Any abnormality prevent reliable applanation tonometry either eye ; Bestcorrected visual acuity bad 20/30 Snellen either eye ; Use additional topical systemic ocular hyposensitive medication study ; Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Intraocular pressure</keyword>
	<keyword>Open-angle glaucoma</keyword>
	<keyword>Ocular hypertension</keyword>
	<keyword>Adherence</keyword>
	<keyword>Compliance</keyword>
</DOC>